All In Biotech

Investigational drug · Phase 3

TG103

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Overweight or Obesity.

Phase 3

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

0 still active

All registered trials

11

Any phase or sponsor naming "TG103"

First trial start

2023

Nov 22, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TG103", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 2 Diabetes Mellitus
  • Overweight or Obesity

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "TG103" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Type 2 Diabetes Mellitus

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • ASC30 A1ASC30Phase 35 trials

    Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight

  • SHR-3167Phase 35 trials

    Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus

  • HTD1801Berberine UrsodeoxycholatePhase 34 trials

    Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes

  • DA-302168SPhase 33 trials

    Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus

  • Exendin-4 Fc fusion proteinJY09Phase 32 trials

    Beijing Dongfang Biotech Co., Ltd. · Type2 Diabetes Mellitus, Type 2 Diabetes Mellitus

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.